WASHINGTON--Feedback indicates that the National Cancer Institute did
quite well in equipping counselors in advance to deal with questions
posed by women about the ability of tamoxifen (Nolvadex) to prevent
breast cancer, NCI director Richard D. Klausner, MD, told a Senate subcommittee.
The agency sought the feedback after announcing the termination of
the Breast Cancer Prevention Trial, run by the National Surgical
Adjuvant Breast and Bowel Project (NSABP). The trial was stopped 14
months early after its monitoring committee determined that patients
receiving tamoxifen (Nolvadex) had a 45% reduction in breast cancer
incidence, compared with the placebo arm.
"The preliminary findings from a survey of cancer center
directors, NCIs Cancer Information Service, principal
investigators of the NSABP, and the advocacy community indicate that
it was possible for them to respond to most inquires and counseling
requests using information already provided by NCI and NSABP,"
Dr. Klausner said.